Proniras Corporation Awarded Contract Worth up to $89.5 Million from BARDA to Develop Nerve Agent Countermeasure

Proniras Corporation, an Accelerator Life Science Partners portfolio company, announced on 4/27/18 that it has been awarded a contract potentially worth $89.5 million from the U.S. Department of Health and Human Service’s Biomedical Advanced Research and Development Authority (BARDA) to develop tezampanel as a medical countermeasure for the treatment of nerve agent-induced seizures that are not stopped by current medications.